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chronic hepatitis C (PLATINUM C): protocol
for a prospective treatment registry of real-
world outcomes for hepatitis C
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Abstract
Background: Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat
chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV)
in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular
carcinoma. Australia is committed to eliminating hepatitis as a public health threat by 2030 set by the World Health
Organization. However, since the introduction of funded DAA treatment, uptake has been suboptimal. Australia
needs improved strategies for testing, treatment uptake and treatment completion to address the persisting
hepatitis C public health problem. PLATINUM C is a HCV treatment registry and research platform for assessing the
comparative effectiveness of alternative interventions for achieving virological cure.
Methods: PLATINUM C will prospectively enrol people with active HCV infection confirmed by recent detection of
HCV ribonucleic acid (RNA) in blood. Those enrolled will agree to allow standardised collection of demographic,
lifestyle, treatment, virological outcome and other relevant clinical data to better inform the future management of
HCV infection. The primary outcome is virological cure evidenced by sustained virological response (SVR), which is
defined as a negative HCV PCR result 6 to 18 months after initial prescription of DAA therapy and no less than 12
weeks after the completion of treatment. Study participants will be invited to opt-in to medication adherence
monitoring and quality of life assessments using validated self-reported instruments (EQ-5D-5L).
Discussion: PLATINUM C is a treatment registry and platform for nesting pragmatic trials. Data collected will inform
the design, development and implementation of pragmatic trials. The digital infrastructure, study procedures and
governing systems established by the registry will allow PLATINUM C to support a wider research platform in the
management of hepatitis C in primary care.
Trial registration: The trial is registered with the Australia and New Zealand Clinical Trials Register
(ACTRN12619000023156). Date of registration: 10/01/2019.
Keywords: Hepatitis C, Direct-acting antiviral treatment, Treatment registry, Platform trial
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: tom.snelling@sydney.edu.au
1Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids
Institute, The University of Western Australia, Perth, Australia
5School of Public Health, Curtin University, Bentley, Australia
Full list of author information is available at the end of the article
Ramsay et al. BMC Infectious Diseases          (2020) 20:802 
https://doi.org/10.1186/s12879-020-05531-4
Background
Hepatitis C in Australia
Hepatitis C virus (HCV) infection is a major public
health issue in Australia and other countries due to the
substantial morbidity associated with chronic infection.
It is estimated 71 million people are living with HCV
worldwide including over 180,000 in Australia [1, 2].
Those chronically infected with HCV, if left untreated,
are at risk of progressive hepatic fibrosis, cirrhosis and
hepatocellular carcinoma.
With the recent development of direct acting antiviral
(DAA) therapy, HCV infection is now curable in the
majority of those infected with drugs that are safe, well
tolerated, and highly effective. In response the World
Health Organization called for the elimination of hepa-
titis C as a public health threat and set targets to reduce
HCV-related mortality by 65% and HCV infection inci-
dence by 80% by 2030 [3].
Australia was one of the first countries globally to
make treatment available for all. From March 2016, all
adults chronically infected with HCV in Australia have
been eligible for treatment with DAA funded by the
Government under the Pharmaceutical Benefit Scheme
(PBS). Implementation of DAA therapies has led to a
shift of HCV management from specialised tertiary care
to the primary care setting. Initially, prescribing the
newly licenced DAAs was complicated by the number of
drugs available and treatment guidelines that factor in
virus genotype, cirrhosis status, previous treatment status,
drug-drug interactions and presence of comorbidities.
If the WHO elimination targets are to be met, effective
strategies are needed to increase the number of people
being tested, treated and cured [4]. These strategies are
still largely unknown. Those most affected by HCV in-
fection are often those who are relatively under-served
by, or who have difficulties accessing, health care [5].
This includes people who inject drugs, incarcerated pop-
ulations, people in rural and remote settings, Indigenous
and migrant populations [6, 7].
Aim
The overall aim of the PLATINUM C treatment registry
is to inform the improved management of HCV in pri-
mary care. It is envisioned that this will provide a re-
search platform to enable the embedding of pragmatic
trials. This protocol outlines the background, objectives,
endpoints, data collection and study procedures generic
to this research platform and sets out the purpose and
rational for establishment of the treatment registry.
Methods/design
Study design
This study is a prospective, multi-site treatment registry
of primary care practices within Australia. Individual
participation in the PLATINUM C research platform
involves the capture of consenting participants’ demo-
graphic and clinical data and HCV treatment and out-
come data. This information will be used to compare
treatment response rates in different subgroups of
patients. Where important variation in practice and
outcomes are identified, this data will be used, as part of
a research prioritisation process, in consultation with the
Platinum C Community Reference Group to inform the
design, development and implementation of pragmatic
trials involving randomised assignment of alternative
treatment options.
Study population and setting
PLATINUM C will enrol adults (≥ 18 years) who have
confirmed active HCV infection (positive HCV RNA
PCR within 3 months) from community primary health
care clinics which are involved in delivering HCV infec-
tion care. Ethical approval has been obtained for 5 high
caseload primary health care clinics across metropolitan
Perth, Western Australia, where the underlining chronic
HCV prevalence ranges between 0.66–0.68%. Additional
study sites across Australia, where the national preva-
lence was estimated to be 0.78% at the start of 2016, will
be included with ethical permission as the study pro-
gresses [8]. Participating clinics will agree to comply with
study procedures including the embedding of the data col-
lection and prescribing tools within their clinical practice.
Objectives
The primary objective of PLATINUM C is, for adults
with chronic HCV infection, to determine the absolute
and comparative effectiveness of a range of interventions
to achieve a HCV virological cure. This is demonstrated
by a sustained viral response (SVR), defined as an
undetectable HCV ribonucleic acid (RNA) ≥12 weeks
after discontinuation of antiviral treatment and within
18months of the start of treatment. Interventions will
include licenced and funded DAA therapies and other
management strategies to be defined by platform em-
bedded trials.
The secondary objectives are to describe chronic HCV
management in primary care for different patient sub-
groups, including by: (i) describing the distribution of
the treatment response under alternative management
options, (ii) characterising treatment adherence, (iii)
identifying demographic and clinical characteristics asso-
ciated with high risk of lost-to-follow-up from standard
care, and (iv) describing and comparing patterns of
health care utilisation.
Outcomes
The primary outcome is virological cure as evidenced by
the endpoint of sustained virological response (SVR)
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defined as a negative HCV RNA (in plasma) PCR result
6 to 18 months after the initial prescription of DAA
therapy and no less than 12 weeks after the end of anti-
viral treatment.
Secondary outcomes and endpoints are:
(i) Completion of follow up defined by the completion
of SVR12 testing (HCV RNA PCR)
(ii) Adherence of study participants to antiviral
treatment recorded as the self-reported proportion
of total prescribed doses taken,
(iii)Quality of life, as measured by the self-reported
EQ-5D-5L questionnaire administered during and
for up to 24 months after initiation of treatment
and,
(iv)Healthcare utilisation defined as any attendance for
healthcare related service that attracts a cost to the
individual, insurer or government.
Study duration
There is no specified end date for the research platform.
It is anticipated that PLATINUM C will continue to
enrol participants and integrate the testing of new inter-
ventions and/or groups of interventions until one of the
following occurs:
 The effectiveness and/or cost-effectiveness of all
possible interventions are known and there are no
new interventions to evaluate
 Chronic HCV infection is no longer deemed to be a
public health problem
 Funding or other necessary support is no longer
available
Should the platform be stopped, the end of this study is
the date of the last scheduled follow up for any participant.
Study procedures
Informed consent
A participant must provide informed consent (written or
electronically) before any specific procedures are per-
formed or data collected. Electronic and/or written
versions of the participant information sheet will be pre-
sented to the participant detailing no less than: the exact
nature of the project; what it will involve for the partici-
pant; the implications and constraints of the protocol;
any risks involved in taking part. It will be clearly stated
that participation is voluntary.
Withdrawal of participants
Participants have the right to withdraw from this study
at any time without penalty or loss of benefits. Data
obtained prior to participants’ withdrawal from the study
will be included in the analysis.
Data collection
Relevant data (outlined in Table 1) will be obtained dir-
ectly from the healthcare providers and participants. Data
will be collected through data capture and prescribing
tools and phone and/or email participant surveys.
PLATINUM C will use a direct data capture tool that
is integrated with the practice software (described in
Fig. 1). Data from consenting participants will be ex-
tracted and uploaded to the data capture system. Infor-
mation unable to be extracted with be uploaded by the
consulting practitioner. The data capture tool will ensure
all information required for prescribing DAAs or referral
for specialist consultation is collected. The data capture
tool will also serve to provide prescribing recommenda-
tion based on the Australia recommendation for geno-
type, cirrhosis level and treatment experience. Patient
information collected will be stored within the practice
software and de-identified participant information will
be fed directly into a secure online database via secure
Table 1 Summary of data collection
Data type Information recorded Time point
Demographics Age, gender, postcode, Indigenous status Enrolment
Lifestyle Self-reported injecting drug use, self-reported alcohol in-take, self-reported housing status,
self-reported reuse of a needle/syringe, self-reported prescribed opioid substitution therapy,
risk of treatment disruption (including imprisonment)
Enrolment
Clinical Hepatitis C history, previous treatment, comorbidities, HCV genotype and RNA level, liver
function tests, liver fibrosis assessment
Treatment prescription
Treatment DAA therapy and duration prescribed, treatment setting, type of prescriber, concurrent
medication, other concurrent HCV management interventions
Treatment prescription
Medication adherence Self-reported adherence to therapy Weekly during treatment course
Quality of life Self-reported quality of life (QoL) score (EQ-5D-5L) 0, 3, 6, 12 and 24 months after
treatment initiation
Outcomes HCV RNA PCR, all re-collected laboratory and imaging results, self-reported injecting
drug use,
3 months after treatment
completion
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middleware. A monitoring dashboard will allow health-
care staff to track when participants are due for follow-
up SVR12 testing and long-term cirrhosis assessments.
Data will be stored on a password protected electronic
database housed securely on a server at the Telethon
Kids Institute in Perth, Western Australia, and will be
archived until 15 years after the end of enrolment or
publication, whichever is later.
Baseline and clinical outcome assessment Prospective
baseline, treatment and outcome data collection will be
integrated into standard clinical care. This information
is currently routinely required in the management of
hepatitis C in Australia as per standard guidelines from
the Gastroenterological Society of Australia and Austra-
lian Liver Association [9]. Embedding of data collection
of clinical information will be facilitated by a HCV pre-
scribing tool.
Life-style questionnaire Participants will be asked to
complete a questionnaire (see Additional file 1) to fur-
ther characterise risk behaviours, treatment responses
and healthcare utilisation across different patient groups
including among marginalised groups who are traditionally
underserved by the healthcare system. These question-
naires were developed in consultation with the Platinum C
Community Reference Group.
Adherence monitoring Participants will be invited to
self-report medication adherence. Upon initiation of
HCV antiviral therapy, participants who opt-in will
receive either a weekly phone or text message asking
them to provide the number of doses taken in the
preceding 7 days.
Quality of life questionnaire The self-reported EQ-5D-
5L quality of life instrument [10] will be issued electronically
to those who opt-in at 0, 3, 6, 12 and 24months after initi-
ation of DAA therapy.
Data analysis
Primary analyses of all data will use the intention-to-
treat (ITT) principle. Demographic, clinical and other
baseline variables will be summarised by viral genotype,
liver cirrhosis status, previous HCV treatment and clin-
ician prescribed treatment. Continuous variables will be
summarised as mean and standard deviation for sym-
metric distributions and median and interquartile range
(IQR) for asymmetric distributions. Categorical variables
will be summarised at each level as frequency and per-
centage. Frequencies below five will be reported as “< 5”
to protect individual confidentiality.
For the primary endpoint a Bayesian logistic regression
model, with weakly informative priors, will be used to
compare treatment groups and incorporate Bayesian
borrowing across pre-specified subgroups. The exact
model will depend on the trial modules (and interven-
tions) defined and will be documented in the statistical
analysis plan (SAP). The proportion of participants that
achieve SVR12 will be reported every 200 participants.
Secondary endpoints will be similarly summarised and
analysed using Bayesian regression models, which will be
documented in the SAP.
Self-reported DAA treatment adherence will be sum-
marised as the median (and IQR) proportion of pre-
scribed doses taken in weeks 1 to 12 by viral genotype,
liver cirrhosis status and clinician prescribed treatment.
Self-reported quality of life measured during and for up
to 24months after initiation of treatment, as measured
by the EQ-5D-5L, will be summarised by median (and
IQR) by viral genotype, liver cirrhosis status and clin-
ician prescribed treatment.
Community and stakeholder involvement
Community and stakeholder involvement has been
central to the development of this research platform and
will continue to serve an important role. Regular con-
sultation of the Platinum C stakeholder advisory com-
mittee and community reference group will help ensure
all procedures, aims and outcomes are of relevance and
importance to those affected by HCV.
Limitations
While we expect engagement with primary care prac-
tices will increase participation in the PLATINUM C
registry, we are limited in our ability to capture all po-
tential participants presenting to study sites. It is likely
some individuals will be treated without being invited to
participate and others will decline. However, the digital
infrastructure created for PLATINUM C aims to make it
easier for prescribers to manage HCV.
Fig. 1 Study workflow and utilisation of the data capture tool
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It is likely that some participants will be lost-to-
follow-up, thereby making outcome information unob-
tainable. This issue has been well-described within the
HCV-infected population [11] and identified as a risk by
our community and stakeholder consultation. As infor-
mation is collected from both prescribers and patients
we anticipate this registry will mitigate this risk by dir-
ectly engaging people infected with HCV and establish-
ing secure data collection.
Future directions
Studies of individual interventions or complex strategies
to better implement DAA therapy are an area of active
research. A limitation of conventional clinical trials is
that even if an intervention is proven effective, it may
not be possible to know whether the benefit of an indi-
vidual intervention is transferable to other contexts.
Also, it can be difficult to identify which element(s) of a
complex intervention are effective (or cost-effective) and
which may be deleterious, especially if implemented in
different treatment settings. Such trials are inefficient for
identifying treatment responsive patient subgroups or
for identifying combinations of interventions which are
synergistic or antagonistic. A platform trial embedded
within the PLATINUM C treatment registry could help
in the evaluation of strategies to optimise the number of
people infected with HCV infection engaging with care,
receiving treatment, and being cured. A large amount of
information is required to adequately design, plan and
implement platform trials, ensuring populations with the
highest burden are adequately represented. PLATINUM
C will do this by implementing a prospective HCV treat-
ment registry using digital data collection and prescrib-
ing tools embedded in primary health care.
Discussion
Safe, highly effective, short course, DAA therapies are
now available to treat chronic HCV infection. Despite
being subsidised by the Australian Government since
2015, it was estimated that only 33% of those infected
had been treated by the end 2018 [12, 13]. To achieve
elimination, strategies are required to increase testing,
treatment uptake and treatment completion in primary
care settings. There are several time and cost barriers
that inhibit embedding of traditional trials within pri-
mary care. We have set out to develop a digital HCV
treatment registry to facilitate DAA prescribing in pri-
mary care, while providing a research platform for nest-
ing pragmatic clinical trials.
Randomised Embedded Multi-Arm Pragmatic (REMA
P) platform trials offer a new approach to optimising the
management of complex conditions [14, 15]; however,
they are complex and require accurate, timely and effi-
cient collection of data. With successful implementation
and integration into routine healthcare, such trials offer
many advantages over traditional clinical trials. Multiple
interventions may be evaluated across different sub-
groups of patients. This novel trial approach is suited to
HCV management in Australia due to the evolving
disease landscape, numerous new treatment and inter-
ventions, the heterogenous disease populations and
Australia’s commitment to disease elimination by 2030.
Any trials embedded within this platform will allow
participants to opt in to receive treatment which is
randomly assigned. This will be achieved by extending
this core protocol through the addition of modules
which will cover all additional procedures for the random
assignment of patients to various treatment options, in-
cluding the capture of adverse events and statistical ana-
lyses. Consistent with the overall objective of PLATINUM
C, all additions and adaptations will evaluate the real-world
effectiveness of HCV treatments and interventions which
aim to achieve virological cure. Implementation of these
trials will be guided by the information collected within the
treatment registry characterising both the patient and pre-
scriber population.
Ensuring quality study procedures such as effective data
collection and obtaining valid informed consent is of
utmost importance for vulnerable participant populations
participating in complex study settings. PLATINUM C
has been designed to establish the digital infrastructure
needed to allow evaluation of alternative interventions and
can therefore accommodate both observational and
randomised, controlled comparative effectiveness studies.
Eligibility is intended to be inclusive for all individuals
eligible for hepatitis C direct acting antiviral therapy. The
creation of digital infrastructure to support registry-nested
trials will facilitate efficient standardised data collection
including capture of endpoints. Shared oversight of the
platform by a joint investigator-consumer steering com-
mittee is expected to support a learning health systems
approach to hepatitis C management in primary care.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05531-4.
Additional file 1. Life-style questionnaire.
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